EUVIMEDEUVIMED entdecken
Open Access

Combined cyclosporine A and urolithin A therapy ameliorates murine lupus nephritis

R Ganugula, K T Babalola, M Arora, V Maruvada, A Pavuluri, S K Karthikeyan, D S Chandrashekar, S Varambally, S K Agarwal, C Mohan, M N V Ravi Kumar

The Journal of Immunology · 15.04.2026 · 215 (4)

DOI: 10.1093/jimmun/vkag087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 13.05.2026. Verfasst von R Ganugula und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, Tuscaloosa, Alabama, 35487, United States. Hauptthemen laut MEDLINE: Lupus Nephritis, Cyclosporine, Immunosuppressive Agents, Coumarins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monotherapies for lupus nephritis (LN) often fail to fully control the disease’s hallmark, renal inflammation and immune complex deposition. This study investigates a novel combination therapeutic strategy using urolithin A (UA), a multifaceted anti-inflammatory and antioxidant agent, with cyclosporine A (CsA), an established immunosuppressant. The combination therapy’s superior efficacy is evidenced by a robust reduction in immunoglobulin G (IgG) anti-dsDNA levels, with markedly improved renal function. The treatment also effectively mitigated immune complex deposition and multiple inflammatory chemokines, including I309, IL-16, and MIP-3. This alleviated kidney damage and suppressed lymphocyte infiltration. We found that CsA alone was ineffective across the analyzed markers, while UA alone produced only a modest effect, highlighting the complementary action of their combination. These findings underscore the potent anti-inflammatory and antioxidant properties of UA and suggest that combining it with CsA offers a more robust strategy for controlling inflammation and preserving renal integrity in LN. Given the FDA-approved status of CsA and UA’s “generally recognized as safe” (GRAS) classification, this combination therapy presents a promising and practical clinical pathway for the treatment of lupus nephritis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisCyclosporineImmunosuppressive AgentsCoumarinsAnti-Inflammatory AgentsAnimalsMiceDrug Therapy, CombinationFemaleDisease Models, AnimalKidneyAntioxidantsImmunoglobulin GAntibodies, AntinuclearAntigen-Antibody Complex

Stichwörter der Autor:innen

combined therapycyclosporine Alupus nephritispro-inflammatory pathwaysurolithin A

Substanzen

CyclosporineImmunosuppressive AgentsCoumarins3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneAnti-Inflammatory AgentsAntioxidantsImmunoglobulin GAntibodies, AntinuclearAntigen-Antibody Complex

Autor:innen und Institutionen

  • The Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, Tuscaloosa, Alabama, 35487, United States.
  • Department of Translational Science and Medicine, College of Community Health Sciences, The University of Alabama, Tuscaloosa, Alabama, 35401, United States.
  • Alabama Life Research Institute, The University of Alabama, Tuscaloosa, Alabama, 35487, United States.
  • Department of Biological Sciences, The University of Alabama, Tuscaloosa , Alabama, 35487, United States.
  • Department of Biomedical Engineering, University of Houston, Houston, Texas, 77204, United States.
  • Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States.

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Ganugula, R., Babalola, K. T., Arora, M., Maruvada, V., Pavuluri, A., Karthikeyan, S. K., Chandrashekar, D. S., Varambally, S., Agarwal, S. K., Mohan, C., & Ravi Kumar, M. N. V. (2026). Combined cyclosporine A and urolithin A therapy ameliorates murine lupus nephritis. The Journal of Immunology, 215(4). https://doi.org/10.1093/jimmun/vkag087

Vancouver

Ganugula R, Babalola KT, Arora M, Maruvada V, Pavuluri A, Karthikeyan SK, et al. Combined cyclosporine A and urolithin A therapy ameliorates murine lupus nephritis. The Journal of Immunology. 2026;215(4). doi:10.1093/jimmun/vkag087

BibTeX
@article{Ganugula2026,
  author = {Ganugula, R and Babalola, K T and Arora, M and Maruvada, V and Pavuluri, A and Karthikeyan, S K and Chandrashekar, D S and Varambally, S and Agarwal, S K and Mohan, C and Ravi Kumar, M N V},
  title = {Combined cyclosporine A and urolithin A therapy ameliorates murine lupus nephritis},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {4},
  doi = {10.1093/jimmun/vkag087}
}
Kostenlos starten →